NIOSHTIC-2 Publications Search
Health hazard evaluation report: HETA-90-0330-2479, New York City Health and Hospitals Corporation, New York, New York.
Deitchman S; Seitz T
Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, HETA 90-0330-2479, 1994 Dec; :1-26
In response to a request from the New York City Health and Hospitals Corporation (NYCHHC) and District Council 37, AFL-CIO, an investigation was begun into possible hazards associated with aerosolized pentamidine (100334) (AP) administration in the facilities of the NYCHHC. In interviews with 12 of 22 exposed workers, workers described symptoms of mucosal irritation. The exposed respondents indicated that they gave an average of 11 pentamidine treatments per week, ranging from 0 to 20. There were no statistically significant differences between the percentages of exposed workers reporting symptoms or illnesses and those of workers not exposed. None of the exposed employees who were tuberculosis purified protein derivative (PPD) skin test negative before AP was introduced had converted to PPD positive on their most recent test. Pentamidine was detected in a single urine specimen from an exposed worker. Personal breathing zone samples and area air samples were taken. Personal breathing zone samples ranged from nondetectable to 46.6 micrograms/cubic meter (microg/m3). The highest personal exposures of 20 and 46microg/m3 were obtained on a nurse and respiratory therapist who were present during drug administration in treatment areas where local exhaust ventilation was not used. The authors conclude that workers administering aerosolized pentamidine were potentially exposed. The authors recommend that efforts be made to reduce worker exposures to aerosolized pentamidine and to Mycobacterium-tuberculosis.
NIOSH-Author; NIOSH-Health-Hazard-Evaluation; NIOSH-Technical-Assistance-Report; HETA-90-0330-2479; Region-2; Hazard-Confirmed; Medical-treatment; Health-care-personnel; Pharmaceuticals; Inhalants; Bacterial-infections; Occupational-exposure; Author Keywords: Hospitals-specialty; pentamidine; pentamidine isethionate; aerosolized pentamidine; AP; tuberculosis; Mycobacterium tuberculosis; health care worker; HIV; Pneumocystis carinii pneumonia
Field Studies; Hazard Evaluation and Technical Assistance
NTIS Accession No.
National Institute for Occupational Safety and Health
Page last reviewed: October 5, 2020
Content source: National Institute for Occupational Safety and Health Education and Information Division